WO2010132047A8 - Guanosine/gmp gels and uses thereof - Google Patents

Guanosine/gmp gels and uses thereof Download PDF

Info

Publication number
WO2010132047A8
WO2010132047A8 PCT/US2009/004189 US2009004189W WO2010132047A8 WO 2010132047 A8 WO2010132047 A8 WO 2010132047A8 US 2009004189 W US2009004189 W US 2009004189W WO 2010132047 A8 WO2010132047 A8 WO 2010132047A8
Authority
WO
WIPO (PCT)
Prior art keywords
gmp
guanosine
gels
particles
aspects
Prior art date
Application number
PCT/US2009/004189
Other languages
French (fr)
Other versions
WO2010132047A1 (en
Inventor
Linda B. Mcgown
Yuehua Yu
Original Assignee
Rensselaer Polytechnic Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytechnic Institute filed Critical Rensselaer Polytechnic Institute
Publication of WO2010132047A1 publication Critical patent/WO2010132047A1/en
Publication of WO2010132047A8 publication Critical patent/WO2010132047A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates in some aspects to guanosine/GMP gel compositions for delivering antibodies, nucleic acids, and particles. In other aspects the invention relates to guanosine/GMP gel compositions and methods of use thereof for controlled-release of antibody, nucleic acid, and micro- and nano-particles.
PCT/US2009/004189 2009-05-14 2009-07-20 Guanosine/gmp gels and uses thereof WO2010132047A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21618309P 2009-05-14 2009-05-14
US61/216,183 2009-05-14
US21651009P 2009-05-15 2009-05-15
US61/216,510 2009-05-15

Publications (2)

Publication Number Publication Date
WO2010132047A1 WO2010132047A1 (en) 2010-11-18
WO2010132047A8 true WO2010132047A8 (en) 2011-01-13

Family

ID=43085241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/004189 WO2010132047A1 (en) 2009-05-14 2009-07-20 Guanosine/gmp gels and uses thereof

Country Status (1)

Country Link
WO (1) WO2010132047A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011121559A2 (en) * 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
EP2552482A2 (en) * 2010-03-31 2013-02-06 Université de Genève Stabilized antibody preparations and uses thereof
FR2995214B1 (en) * 2012-09-10 2014-11-21 Adocia REDUCED VISCOSITY SOLUTION OF HIGH CONCENTRATION PROTEIN
EP3043775B1 (en) * 2013-09-11 2020-11-04 Eagle Biologics, Inc. Liquid protein formulations containing viscosity-lowering agents
US9549914B2 (en) 2014-04-03 2017-01-24 The Johns Hopkins University Treatment of human cytomegalovirus by modulating Wnt
KR102497368B1 (en) 2014-10-01 2023-02-10 이글 바이올로직스 인코포레이티드 Polysaccharide and nucleic acid formulations containing viscosity-lowering agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE459634T1 (en) * 2005-03-24 2010-03-15 Firmenich & Cie HYDROGELS FOR THE CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE MATERIALS
US7737188B2 (en) * 2006-03-24 2010-06-15 Rensselaer Polytechnic Institute Reversible biogel for manipulation and separation of single-walled carbon nanotubes

Also Published As

Publication number Publication date
WO2010132047A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
CL2013000074A1 (en) Binding protein with the ability to bind a pair of antigens; nucleic acid encoding it; vector; host cell; Method of production; pharmaceutical composition that includes it; conjugate comprising said binding protein; and its uses
WO2012024526A3 (en) Conjugates, particles, compositions, and related methods
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
WO2015089511A3 (en) Modified nucleic acid molecules and uses thereof
IL221205A0 (en) Antibody drug conjugates (adc) that bind to 161p2f10b proteins, compositions comprising the same and uses thereof
MX2015008446A (en) Multivalent binding protein compositions.
EP3722320A3 (en) Anti-complement c1s antibodies and uses thereof
HK1215954A1 (en) Btnl9 proteins, nucleic acids, and antibodies and uses thereof btnl9
EP3029066A3 (en) Antibodies with modified isoelectric points
CA2865594C (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
WO2010132047A8 (en) Guanosine/gmp gels and uses thereof
WO2011005799A3 (en) Rna containing modified nucleotides and use thereof in vaccines
WO2015017527A3 (en) Methods for the production of long length clonal sequence verified nucleic acid constructs
EP3107107A3 (en) Highly active silica magnetic nanoparticles for purifying biomaterial and preparation method thereof
MX336682B (en) Antibodies against human csf-1r and uses thereof.
WO2013048883A3 (en) Anti-erbb3 antibodies and uses thereof
MX2009003306A (en) Human antibodies that bind cxcr4 and uses thereof.
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
IL237345B (en) Antibody drug conjugates (adc) that bind to 158p1d7 proteins, compositions comprising the same and uses thereof
WO2012009544A3 (en) Domain insertion immunoglobulin
WO2012010974A8 (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
IL211866A0 (en) Antibodies that bind to il-12 and methods of purifying the same
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
UA105073C2 (en) Anti-fractalkine antibody, composition and method for treating inflammatory disorders
MX2010001723A (en) Formulations of antibodies and fc-fusion molecules using polycations.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09844730

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09844730

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI0924268

Country of ref document: BR